TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Rechon Life Science AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
575,080
|
492,266
|
367,251 |
| Financial expenses |
4,066
|
3,171
|
1,226 |
| Earnings before taxes |
61,018
|
57,164
|
56,996 |
| EBITDA |
84,422
|
79,730
|
73,626 |
| Total assets |
501,633
|
369,072
|
309,265 |
| Current assets |
275,846
|
207,660
|
159,166 |
| Current liabilities |
148,186
|
102,193
|
75,502 |
| Equity capital |
257,254
|
205,607
|
160,492 |
| - share capital |
28,403
|
27,900
|
26,051 |
| Employees (average) |
286
|
249
|
212 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
51.3%
|
55.7%
|
51.9% |
| Turnover per employee |
2,011
|
1,977
|
1,732 |
| Profit as a percentage of turnover |
10.6%
|
11.6%
|
15.5% |
| Return on assets (ROA) |
13.0%
|
16.3%
|
18.8% |
| Current ratio |
186.1%
|
203.2%
|
210.8% |
| Return on equity (ROE) |
23.7%
|
27.8%
|
35.5% |
| Change turnover |
73,939
|
98,956
|
78,132 |
| Change turnover % |
15%
|
25%
|
27% |
| Chg. No. of employees |
37
|
37
|
28 |
| Chg. No. of employees % |
15%
|
17%
|
15% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.